Immunology company Zura Bio Limited (Nasdaq: ZURA) announced on Monday that it has initiated TibuSURE, a Phase 2 global study to evaluate tibulizumab for systemic sclerosis (SSc) in adults. The trial is the first to explore dual inhibition of BAFF and IL-17 pathways in this rare autoimmune disease.
TibuSURE will assess the safety, tolerability and efficacy of tibulizumab in approximately 80 participants with early diffuse cutaneous systemic sclerosis over a 24-week period, followed by a 28-week open-label extension. Key endpoints include the modified Rodnan Skin Score, lung function measures and patient-reported outcomes.
Systemic sclerosis affects 300,000 individuals globally and has limited treatment options. Tibulizumab, a bispecific antibody targeting IL-17A and BAFF, aims to address the disease's multisystem impact.
Zura Bio is also advancing tibulizumab for hidradenitis suppurativa, with Phase 2 trials planned for 2025. The company's portfolio includes additional assets, crebankitug and torudokimab, targeting autoimmune and inflammatory conditions with high unmet needs.
Eli Lilly's Omvoh receives US FDA approval
Incyte and Syndax receive US FDA approval for Niktimvo (axatilimab-csfr) in 9 mg and 22 mg vials
Sen-Jam Pharmaceutical receives ethics approval for Australian clinical trial of SJP-001
PacBio and Intus Bio launch GutID, first at-home microbiome test powered by HiFi sequencing
Veralox Therapeutics agrees Nudge Therapeutics acquisition
Xentria announces operational expansion of multiple clinical trials in 2025
Insilico Medicine reports positive results from Phase I ISM5411 studies in Australia and China
Chime Biologics and Mabgeek completes Process Performance Qualification for MG-K10
argenx receives Japanese approval for VYVDURA in chronic inflammatory demyelinating polyneuropathy